Preclinical And Clinical Immuno-PET to Empower Development Of Antibody Therapeutics

Time: 2:45 pm
day: Track A


  • Overview of immuno-PET probes and considerations common with targeted radionuclide therapies
  • Demonstrate the value of preclinical immuno-PET in the development of antibody-based therapeutics including T-cell engaging bispecifics and ADCs
  • Illustrate the challenges and opportunities in the clinical application of immuno-PET agents in diagnostic/ prediction of response applications for cancer immunotherapies